Special Issue

The Role of Hedgehog Pathway in Cancer

Message from the Guest Editors

Aberrant activation of the Hedgehog pathway is implicated in the development of a variety of tumors. As a result, the Hedgehog pathway represents an attractive therapeutic target for cancer treatment. Although drugs targeting this pathway have produced promising clinical results and have been approved for basal cell carcinoma, they have demonstrated so far limited clinical efficacy against most cancer types. Therefore, we need to deepen our understanding on how the Hedgehog pathway functions during tumor development and progression, and how it interacts with other signaling pathways. In this Special Issue, We will collect original articles and reviews that provide new insights into the Hedgehog signaling in cancer, including, but not limited to: mechanisms of canonical and non-canonical activation; regulation of GLI transcription factors; function of the Hedgehog pathway in cancer cells stemness, cancer metabolism and metastasis; role of Hedgehog signaling in the tumor microenvironment; miRNA and Hedgehog signalling; novel strategies to inhibit the Hedgehog signaling; mechanism of resistance to Hedgehog-targeted therapy and approaches to overcoming this resistance.

Guest Editors

Prof. Enrico De Smaele

Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 29, 00161 Roma, Italy

Dr. Barbara Stecca

Tumor Cell Biology Unit, Core Research Laboratory, Istituto per lo Studio la Prevenzione e la Rete Oncologica (ISPRO), 50139 Firenze, Italy

Deadline for manuscript submissions

closed (20 July 2022)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/71195

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)